

Ship Meds to:  Patient's Home  Prescriber's Office

**Prescriber Information**

|                  |      |        |   |  |      |  |
|------------------|------|--------|---|--|------|--|
| Prescriber Name: |      |        | <input type="radio"/> MD <input type="radio"/> DO <input type="radio"/> NP <input type="radio"/> PA |  | NPI: |  |
| Office Contact:  |      |        | Practice Name / Collaborating Physician:  |  |      |  |
| Address:         |      |        | City:   |  |      |  |
| State:           | Zip: | Phone: | Fax:  |  |      |  |

**Patient Information | PLEASE SEND COPY OF INSURANCE CARD**

|                 |                       |                |  |   |         |   |
|-----------------|-----------------------|----------------|--|---|---------|---|
| Patient's Name: | Last 4 Digits of SS#: | DOB: / /       | Sex: <input type="radio"/> M <input type="radio"/> F | Weight:   | Height: | Diabetic: <input type="radio"/> Y <input type="radio"/> N |
| Address:        | City:                 | State:         | Zip:   | Allergies:  |         |   |
| Home Phone:     | Work Or Cell:         | HIPAA Contact: | Emergency #:   | Interpreter Needed? <input type="radio"/> Y <input type="radio"/> N |         |   |

**Insurance Information**

|                    |                   |          |      |
|--------------------|-------------------|----------|------|
| Primary Insurance: | Policy ID:        | Group #: |      |
| Policyholder Name: | Policyholder DOB: | BIN:     | PCN: |

**Clinical Information | PLEASE SEND COPY OF MEDICAL AND PRESCRIPTION INSURANCE CARDS, PROGRESS NOTES AND LAB REPORTS, SUPPORTING DIAGNOSIS, CO-MORBIDITIES AND LAB VALUES**

|   |  |  |                          |                     |
|---|--|--|--------------------------|---------------------|
| ICD-10 Code:                                  | Weight _____ <input type="radio"/> lb / <input type="radio"/> kg | Height _____ <input type="radio"/> in / <input type="radio"/> cm | BSA _____ m <sup>2</sup> | Diagnosis Date: / / |
| Current SCR _____ or current GFR _____ ml/min | Confirmed Mutations:   |  |                          |                     |
| Prior Therapy                                 | Reason for Discontinuation of Therapy                            | Approximate Start Date   | Approximate End Date     |                     |

**Prescription Information**

| Medication   | Dose/Strength  | Sig (Please Include Cycle) | Quantity | Refills |
|--|--|----------------------------|----------|---------|
| <input type="radio"/> <b>ABRAXANE®</b><br>(paclitaxel protein-bound)   | <input type="radio"/> 100mg vial   |                            |          |         |
| <input type="radio"/> <b>ADCETRIS®</b><br>(brentuximab vedotin)  | <input type="radio"/> 50mg vial  |                            |          |         |
| <input type="radio"/> <b>ALIMTA®</b><br>(pemetrexed)   | <input type="radio"/> 100mg vial<br><input type="radio"/> 500mg vial                               |                            |          |         |
| <input type="radio"/> <b>ARZERRA®</b><br>(ofatumumab)  | <input type="radio"/> 100mg/5mL vial<br><input type="radio"/> 1000mg/50mL vial                     |                            |          |         |
| <input type="radio"/> <b>AVASTIN®</b><br>(bevacizumab)<br><br>Biosimilars:<br><input type="radio"/> Mvasi™<br><input type="radio"/> Zirabev®   | <input type="radio"/> 100mg vial<br><input type="radio"/> 400mg vial                               |                            |          |         |
| <input type="radio"/> <b>CLOLAR®</b><br>(clofarabine)  | <input type="radio"/> 20mg vial  |                            |          |         |
| <input type="radio"/> <b>CYCLOPHOSPHAMIDE</b>  | <input type="radio"/> 500mg vial<br><input type="radio"/> 1g vial<br><input type="radio"/> 2g vial |                            |          |         |
| <input type="radio"/> <b>EMPLICITI®</b><br>(elotuzumab)  | <input type="radio"/> 300mg vial<br><input type="radio"/> 400mg vial                               |                            |          |         |
| <input type="radio"/> <b>ERBITUX®</b><br>(cetuximab)   | <input type="radio"/> 100mg/50mL vial<br><input type="radio"/> 200mg/100mL vial                    |                            |          |         |
| <input type="radio"/> <b>HALAVEN®</b><br>(eribulin mesylate)   | <input type="radio"/> 1mg/2mL vial   |                            |          |         |
| <input type="radio"/> <b>HERCEPTIN®</b><br>(trastuzumab)<br><br>Biosimilars:<br><input type="radio"/> Herzuma® <input type="radio"/> Ontruzant®<br><input type="radio"/> Kanjinti™ <input type="radio"/> Trazimera™<br><input type="radio"/> Ogivri™ | <input type="radio"/> 150mg vial<br><input type="radio"/> 420mg vial (biosimilars only)            |                            |          |         |

By signing this form and utilizing our services, you are authorizing Meijer and its employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.

|                       |      |                       |      |
|-----------------------|------|-----------------------|------|
| Prescriber Signature: | Date | Prescriber Signature: | Date |
|-----------------------|------|-----------------------|------|

Substitution Permitted

Dispense as Written

If brand is required, please write "DAW" in the box to the right.